Sveriges mest populära poddar
BiotechTV - News
VetenskapLife Science

Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD

13 min•17 februari 2026

The study showed that AXPAXLI has superior maintenance of visual acuity at Week 36 vs EYLEA. Dr. Dugel discusses what he believes the significance of this is, and delves into durability data going out to 52 weeks.

Fler avsnitt av BiotechTV - News

Visa alla avsnitt av BiotechTV - News
ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs
•35 min
ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications
•13 min
London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors
•17 min
Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process
•23 min
Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination
•23 min
Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip
•17 min
Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more
•42 min
Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar
•14 min
10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform
•14 min
Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated
•26 min

BiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.